JP2019534261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534261A5 JP2019534261A5 JP2019518440A JP2019518440A JP2019534261A5 JP 2019534261 A5 JP2019534261 A5 JP 2019534261A5 JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019534261 A5 JP2019534261 A5 JP 2019534261A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- compound according
- acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC*(CC**c1n*(*)c(C(*=C2)=**2N*)[n]1)C(C(*)(*)*(CC1)CC1(CC*1C2=*CC(C(**)=**3(C)C)=C3C=C2)C1=O)=O Chemical compound CCC*(CC**c1n*(*)c(C(*=C2)=**2N*)[n]1)C(C(*)(*)*(CC1)CC1(CC*1C2=*CC(C(**)=**3(C)C)=C3C=C2)C1=O)=O 0.000 description 3
- MBVCTQKXEGCCCL-UHFFFAOYSA-N CC(O1)=NN(C)C1=O Chemical compound CC(O1)=NN(C)C1=O MBVCTQKXEGCCCL-UHFFFAOYSA-N 0.000 description 1
- HZMBHUAOZYMRMM-UHFFFAOYSA-N CCCN(CCC(N(CC)c(nc12)ccc1[nH]nc2-c1ccc2[nH]nc(C)c2c1)=O)CC(N(CC1)CC=C1c(cc1)ccc1-c1n[n](C)cn1)=O Chemical compound CCCN(CCC(N(CC)c(nc12)ccc1[nH]nc2-c1ccc2[nH]nc(C)c2c1)=O)CC(N(CC1)CC=C1c(cc1)ccc1-c1n[n](C)cn1)=O HZMBHUAOZYMRMM-UHFFFAOYSA-N 0.000 description 1
- GNZLMOPUFWAWCM-UHFFFAOYSA-N CCN(C(C1(C)CN(CC(N(CC2)CC=C2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C(C1(C)CN(CC(N(CC2)CC=C2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1OC(C)C GNZLMOPUFWAWCM-UHFFFAOYSA-N 0.000 description 1
- QXAXJRFSRONTIN-RMVMEJTISA-N CCN(C(C1)C=Cc2c1c(-c(nc1)ccc1[F]C)n[nH]2)C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O Chemical compound CCN(C(C1)C=Cc2c1c(-c(nc1)ccc1[F]C)n[nH]2)C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O QXAXJRFSRONTIN-RMVMEJTISA-N 0.000 description 1
- DCSWJQOSZKSFEZ-UHFFFAOYSA-N CCN(C(C1=CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cn1)ccc1OC Chemical compound CCN(C(C1=CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cn1)ccc1OC DCSWJQOSZKSFEZ-UHFFFAOYSA-N 0.000 description 1
- IAYZAOMOUHPOLI-UHFFFAOYSA-N CCN(C(C1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c1ccc2[o]nc(C)c2c1 Chemical compound CCN(C(C1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c1ccc2[o]nc(C)c2c1 IAYZAOMOUHPOLI-UHFFFAOYSA-N 0.000 description 1
- RUBGBTVEESZOCD-QASNXKAYSA-N CCN(C(C1[C@@H](C)CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)C1)=O)c(nc12)ccc1[nH]nc2-c(c(F)c1)ccc1[ClH]C Chemical compound CCN(C(C1[C@@H](C)CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)C1)=O)c(nc12)ccc1[nH]nc2-c(c(F)c1)ccc1[ClH]C RUBGBTVEESZOCD-QASNXKAYSA-N 0.000 description 1
- NDPMJKQHUDUIKM-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N NDPMJKQHUDUIKM-SSEXGKCCSA-N 0.000 description 1
- ITMAOYQVJCZFGA-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cc(OC)c1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cc(OC)c1OC(C)C ITMAOYQVJCZFGA-SSEXGKCCSA-N 0.000 description 1
- DVYAVLSWFJARNY-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1OC)ccc1OC1CC1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1OC)ccc1OC1CC1 DVYAVLSWFJARNY-MUUNZHRXSA-N 0.000 description 1
- MDKYGHNCPWMSJJ-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1OC(C)C MDKYGHNCPWMSJJ-WJOKGBTCSA-N 0.000 description 1
- CULMORASYYAQGQ-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(nc1N2CCCC2)ccc1F Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(nc1N2CCCC2)ccc1F CULMORASYYAQGQ-GDLZYMKVSA-N 0.000 description 1
- HSLXVKOJYMNMNE-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)ccc1C#[N]C HSLXVKOJYMNMNE-SSEXGKCCSA-N 0.000 description 1
- RRAOYXXXEMFIES-MUUNZHRXSA-O CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=[NH2+])=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=[NH2+])=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(nc1)ccc1C#N RRAOYXXXEMFIES-MUUNZHRXSA-O 0.000 description 1
- LYEJXIHOCDMNLO-HHHXNRCGSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccc(C)nc1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccc(C)nc1 LYEJXIHOCDMNLO-HHHXNRCGSA-N 0.000 description 1
- HAJBINBHTWYDAK-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ccc(-c3n[n](C)cn3)nc2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)ccc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ccc(-c3n[n](C)cn3)nc2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)ccc1OC(C)C HAJBINBHTWYDAK-MUUNZHRXSA-N 0.000 description 1
- WTKZDLSBVYKJJB-RUZDIDTESA-N CCN(C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccnc(C)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CCN2c(nc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c1ccnc(C)c1 WTKZDLSBVYKJJB-RUZDIDTESA-N 0.000 description 1
- KJUGBSAKKMBCRD-LBNVMWSVSA-N CCN(C([C@H]1CN(CC(N(CC2)[C@@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)[C@@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(nc12)ccc1[nH]nc2-c(cc1)cnc1OC(C)C KJUGBSAKKMBCRD-LBNVMWSVSA-N 0.000 description 1
- KJUGBSAKKMBCRD-LEAFIULHSA-N CCN(C([C@H]1CN(CC(N(CC2)[C@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)[C@H](C)CN2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)nc2c1[nH]nc2-c(cc1)cnc1OC(C)C KJUGBSAKKMBCRD-LEAFIULHSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021154677A JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| US62/404,668 | 2016-10-05 | ||
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Division JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534261A JP2019534261A (ja) | 2019-11-28 |
| JP2019534261A5 true JP2019534261A5 (enExample) | 2020-11-12 |
| JP6949952B2 JP6949952B2 (ja) | 2021-10-13 |
Family
ID=61831517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518440A Expired - Fee Related JP6949952B2 (ja) | 2016-10-05 | 2017-10-03 | スピロ環化合物 |
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (enExample) |
| EP (1) | EP3523306A4 (enExample) |
| JP (2) | JP6949952B2 (enExample) |
| KR (1) | KR20190075931A (enExample) |
| CN (1) | CN109890827A (enExample) |
| AU (1) | AU2017339890A1 (enExample) |
| BR (1) | BR112019005305A2 (enExample) |
| CA (1) | CA3037064A1 (enExample) |
| IL (1) | IL265752A (enExample) |
| MX (1) | MX2019003938A (enExample) |
| RU (1) | RU2019107667A (enExample) |
| TW (1) | TW201817732A (enExample) |
| WO (1) | WO2018067512A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3277690B1 (en) | 2015-04-03 | 2020-02-26 | Recurium IP Holdings, LLC | Spirocyclic compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| AU2019334264B2 (en) * | 2018-09-07 | 2024-10-31 | Merck Patent Gmbh | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) * | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN122094959A (zh) * | 2023-10-31 | 2026-05-26 | C4医药公司 | 用于降解突变体braf的化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2897422T3 (es) * | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES2372976T3 (es) * | 2005-12-13 | 2012-01-30 | Schering Corporation | Derivados de indazol policíclicos que son inhibidores de erk. |
| JP5380296B2 (ja) | 2006-11-17 | 2014-01-08 | ポリエラ コーポレイション | ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法 |
| MX2009014208A (es) * | 2007-06-18 | 2010-01-28 | Schering Corp | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. |
| EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| WO2013033059A1 (en) * | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| JP6322770B2 (ja) | 2014-12-22 | 2018-05-09 | イーライ リリー アンド カンパニー | Ｅｒｋ阻害剤 |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3277690B1 (en) * | 2015-04-03 | 2020-02-26 | Recurium IP Holdings, LLC | Spirocyclic compounds |
-
2017
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019107667A (ru) | Спироциклические соединения | |
| JP2024102236A5 (enExample) | ||
| US20240092794A1 (en) | Novel prmt5 inhibitors | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| EP4251624A1 (en) | Tricyclic carboxamide derivatives as prmt5 inhibitors | |
| EP4598916A1 (en) | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| JPWO2020122093A5 (enExample) | ||
| JP2013523884A5 (enExample) | ||
| JP2019514878A5 (enExample) | ||
| NZ630467A (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| JP2012528828A5 (enExample) | ||
| DK2831077T3 (en) | BICYCLIC PYRAZINO DERIVATIVES | |
| KR20210091954A (ko) | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
| IL256964A (en) | Csf-1r receptor antagonists | |
| KR101697444B1 (ko) | 다이옥시노- 및 옥사진-[2,3-d]피리미딘 pi3k 억제제 화합물 및 사용 방법 | |
| ME02635B (me) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
| KR20140014149A (ko) | 세린/트레오닌 키나제 저해제로서의 신규 아자인돌릴페닐 설폰아미드 | |
| RU2015149937A (ru) | Соединения для модулирования киназы и показания к их применению | |
| EP2356116A1 (en) | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines | |
| JP2016531858A5 (enExample) | ||
| CN110964012B (zh) | 一类稠杂环联芳基苄醇类化合物、制备方法和用途 | |
| RU2010128221A (ru) | Соединения тиенопиридазина, их получение, содержащие их фармацевтические композиции и их применение | |
| JP2012525367A5 (enExample) | ||
| RU2016105999A (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их |